KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919

Author :

Publish date : 2025-08-08 20:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

Rapist Who Killed Visiting Nurse Gets 50 Years in Prison

A planet the size of Saturn could orbit the nearest Sun-like star

Related Posts

‘Why Change What Works?’: What We Heard This Week

I Have a Wealth of Patient Stories. But I Choose to Write Fiction.

Cold-Water Immersion May Offer Health Benefits, and Also Presents Risks

Door Closes on Aggressive Perioperative BP Targets for Select Patients

‘My late husband’s organs transformed the lives of four people’

3 Survivors Share Their Remission Stories

‘Why Change What Works?’: What We Heard This Week

I Have a Wealth of Patient Stories. But I Choose to Write Fiction.

Cold-Water Immersion May Offer Health Benefits, and Also Presents Risks

Door Closes on Aggressive Perioperative BP Targets for Select Patients

‘My late husband’s organs transformed the lives of four people’

3 Survivors Share Their Remission Stories

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Categories

Archives